Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, specifically reporting on transactions executed on February 10, 2021. The filing details the granting of awards under the company's Deferred Investment Award Programme to Persons Discharging Managerial Responsibilities (PDMRs) to support retention and align long-term interests with shareholders.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation transactions.
- Share Price: The closing Ordinary Share price used to determine awards was £12.75.
- Award Type: Restricted awards of notional Ordinary Shares (paid in cash upon vesting).
- Total Notional Volume: 274,509.805 notional shares granted across four executives.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document serves as a regulatory notification of specific equity-based compensation grants rather than a financial performance update.
Guidance, Outlook, and Management Commentary
The filing outlines the vesting schedule for the 2021 awards: 50% on February 10, 2024; 25% on February 10, 2025; and the balance on February 10, 2026. Vesting is conditional on the PDMR remaining in service and not being terminated for cause. Dividends accrue during the vesting period through reinvestment in additional notional shares. Executive Directors are explicitly noted as ineligible for this specific programme.
Recipients and Award Details
| Name | Position | Notional Volume |
|---|---|---|
| Mr R Connor | President, Global Vaccines | 78,431.373 |
| Mr L Miels | President, Global Pharmaceuticals | 78,431.373 |
| Mr R Simard | President, Pharmaceuticals Supply Chain | 39,215.686 |
| Ms D Waterhouse | CEO of ViiV Healthcare | 78,431.373 |
Important Facts for Investors to Verify
- Confirm the total dilution impact of notional share awards on future cash payouts.
- Verify the specific performance conditions or service requirements attached to the vesting schedule.
- Check subsequent filings for any changes in the status of the named PDMRs that could affect vesting.
- Note that this filing contains no data on GSK's broader financial health or operational results for the period.